Rifabutin how supplied: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
Gerald Chi (talk | contribs) mNo edit summary |
||
| (One intermediate revision by one other user not shown) | |||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Rifabutin }} | {{Rifabutin}} | ||
{{CMG}}; {{AE}} {{chetan}} | {{CMG}}; {{AE}} {{chetan}} | ||
==How Supplied== | ==How Supplied== | ||
| Line 17: | Line 15: | ||
{| | {| | ||
|- | |- | ||
| [[File:|800px|thumb]] | | [[File:RIFABUTIN8.jpg|800px|thumb]] | ||
|- | |- | ||
|} | |} | ||
Latest revision as of 03:24, 4 January 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Chetan Lokhande, M.B.B.S [2]
How Supplied
MYCOBUTIN Capsules (rifabutin capsules, USP) are supplied as hard gelatin capsules having an opaque red-brown cap and body, imprinted with MYCOBUTIN/PHARMACIA & UPJOHN in white ink, each containing 150 mg of rifabutin, USP.
MYCOBUTIN is available as follows:
NDC 0013-5301-17 Bottles of 100 capsules
Keep tightly closed and dispense in a tight container as defined in the USP. Store at 25°C (77°F); excursions permitted to 15°–30°C (59°–86°F) [see USP Controlled Room Temperature].[1]
 |
References
- ↑ "MYCOBUTIN (RIFABUTIN) CAPSULE [PHARMACIA AND UPJOHN COMPANY]". Text " accessdate " ignored (help)
Adapted from the FDA Package Insert.